Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Oxford
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Oxford, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 19 Leeds 18 Birmingham 11 Bournemouth 9 Oxford 8
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Oxford

8 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
BeOne Medicines
Phase 3
500
Brighton, Canterbury, Norwich, Oxford, Roundhay, Salisbury
2025-09-04
Recruiting
Eli Lilly and Company
Phase 4
279
Leeds, Oxford, Plymouth
2025-05-20
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Eli Lilly and Company
Phase 4
787
Leeds, Oxford, Plymouth
2025-05-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Bristol, Lancaster, London, Oxford, Newmarket, Windsor, Barnet, Leeds
2023-12-13
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Merck Sharp & Dohme LLC
Phase 2
189
Truro, London, Oxford, Manchester
2022-07-21
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Birmingham, Leeds, Leicester, London, Oxford, Plymouth
2021-09-20
Active, closed
Acerta Pharma BV
Phase 1
12
Birmingham, Bournemouth, Cardiff, Leeds, London, Nottingham, Oxford, Southampton
2018-01-31
Active, closed
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
NCT02029443Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
Acerta Pharma BV
Phase 1/2
306
Leeds, London, Oxford
2014-01-30
Rows per page Showing 1–8 of 8
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-uk/city/oxford

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 11 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 8 of those studies with a site in Oxford that also match the filters currently applied.

How many clinical trials are recruiting in Oxford?

4 of the 8 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Oxford), 8 studies
PhaseStudiesRecruitingShare
Phase 33237.5%
Phase 42225%
Phase 11012.5%
Phase 1/21012.5%
Phase 21012.5%

Most active sponsors

Lead sponsors with the most studies (Oxford)
Lead sponsorStudiesRecruiting
Acerta Pharma BV20
Eli Lilly and Company22
Merck Sharp & Dohme LLC21
BeOne Medicines11
Loxo Oncology, Inc.10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.